Thelansis

  Progressive multiple sclerosis (PMS) represents a clinical variant of MS characterized by a gradual accumulation of disability, independent of relapses, over time. Secondary progressive MS (SPMS) emerges after an initial relapsing phase of the disease, while primary progressive MS (PPMS) manifests with a gradual disability accrual from disease onset. PPMS constitutes the initial disease presentation in approximately 10% of patients, and a substantial proportion of individuals with relapsing-remitting MS (RRMS) eventually transition to SPMS. Unlike the significant progress in managing RRMS, where inflammation can be targeted to modify the disease course, no specific treatment has been identified for purely progressive forms of MS. This therapeutic gap highlights an incomplete understanding of PMS pathogenesis, a lack of validated outcome measures, and predominantly adverse clinical trial outcomes. Thelansis’s “Progressive Multiple Sclerosis (PMS) Market Outlook, Epidemiology...